Skip to main content

Over the past decade advances in technology and understanding have progressed the microbiome arena into a multi-billion-euro industry. SeqBiome which has unparalleled experience and expertise in the space is a major beneficiary of this expansion and is now working with some of the world’s largest pharmaceutical, biotech and food companies across Europe and the USA. In anticipation of further growth, the Company is strengthening its board of directors.
Serving as a Non-Executive Board Director, Frank will bring 30-years of experience building shareholder-value in early-stage companies.

“The ability to quickly and expertly analyse a diverse range of microbiomes is a really timely proposition. A wide variety of life-sciences companies, from pharma to food, are interested in developing new microbiome-related products and services. SeqBiome is at the leading edge of this trend, and I am excited to join their board and help drive growth and an outcome for all shareholders”, said Frank Walsh, newly nominated to join The SeqBiome Board of Directors.

“I am absolutely delighted that we crossed paths and now have Frank on our side to help take Seqbiome to new heights. Frank has been on the start-up journey across so many companies we are delighted to be able to tap into his network and knowledge”, said Marcus Claesson, co-founder and CEO of SeqBiome.